This is a positive but early-stage pipeline validation with no near-term catalyst. The company's financial distress (going concern, $4.1M cash per 20-F) and ongoing ATM dilution (up to $2.59M additional ADSs filed Oct 13) dominate the risk profile. Monitor for enrollment updates and any partnership or financing news that addresses the cash runway.
Price Chart
Executive Summary
RedHill Biopharma announced a $2.9 million NCI grant to the University of Oklahoma for clinical trials combining opaganib with CAR T-cell therapy in ultra-high-risk multiple myeloma. The five-year grant will fund a Phase 1b (up to 18 patients) and Phase 2 (up to 21 patients) trial. This is a non-dilutive, early-stage academic collaboration with no near-term revenue impact, occurring against a backdrop of severe financial distress (going concern warning in the 20-F) and a recent ATM offering filing for up to $2.59 million in additional ADS sales.
Key Facts
- NCI awarded a $2.9 million, five-year grant to the University of Oklahoma for clinical trials of opaganib + CAR T-cell therapy in ultra-high-risk multiple myeloma.
- Phase 1b trial plans to enroll up to 18 patients; Phase 2 plans up to 21 additional patients.
- RedHill will provide opaganib; the CAR construct was developed by Lentigen Technology (Miltenyi Biotec).
- The grant is non-dilutive and covers trial costs; RedHill's financial contribution is limited to drug supply.
- The filing follows a 424B5 (Oct 13, 2026) that increased the ATM offering capacity by up to $2,587,409 in ADSs.
- The prior 20-F (Apr 27, 2026) disclosed substantial doubt about going concern with only $4.1M cash remaining.
Financial Impact
Non-dilutive $2.9M NCI grant; no direct revenue or cost impact to RedHill beyond drug supply. The company concurrently filed to sell up to $2.59M in additional ADSs under its ATM facility.
Risk Factors
- Going concern risk per 20-F; only $4.1M cash as of year-end 2025.
- Ongoing ATM dilution; up to $2.59M in additional ADSs registered on Oct 13, 2026.
- Trials are early-stage (Phase 1b/2) with no guarantee of safety or efficacy; results years away.
- Nasdaq minimum bid price compliance risk remains.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-004786 |
| Document: zk2636236.htm | 0001178913-26-004786 |
| Document: 0001178913-26-004786-index-headers.html | 0001178913-26-004786 |
| Document: 0001178913-26-004786-index.html | 0001178913-26-004786 |
| Document: 0001178913-26-004786.txt | 0001178913-26-004786 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.4550 | awaiting T+60 | — | $0.4230 (−7.03%) |
Oct 19, 2026 7d ago | 6-K | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 19, 2026 7d ago | Press Release | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 13, 2026 12d ago | 6-K | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 13, 2026 12d ago | 424B5 | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 7, 2026 19d ago | 6-K | $0.4740 | awaiting T+60 | — | $0.4230 (−10.76%) |
Sep 1, 2026 7w ago | 6-K | $0.8700 | awaiting T+60 | — | $0.4230 (−51.38%) |
Aug 31, 2026 8w ago | 6-K | $0.9000 | awaiting T+60 | — | $0.4230 (−53.00%) |
Aug 7, 2026 11w ago | 6-K | $0.6050 | awaiting T+60 | — | $0.4230 (−30.08%) |
Aug 6, 2026 11w ago | 6-K | $0.5810 | awaiting T+60 | — | $0.4230 (−27.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers